Emergent BioSolutions | EBS - Ativo Circulante





Ativo Circulante Alterar Data
Acadia Pharmaceuticals USD 1.22B 128.53M 2026-06
Akebia Therapeutics USD 229.55M 13.93M 2026-06
ALKERMES USD 1.52B 164.26M 2026-06
Alnylam Pharmaceuticals USD 4.62B 400.86M 2026-06
Amarin USD 602.76M 23.26M 2026-06
ANI Pharmaceuticals USD 825.43M 78.35M 2026-06
BioMarin Pharmaceutical USD 3.97B 633.45M 2026-06
Coherus Biosciences USD 133.79M 72.25M 2026-06
Emergent BioSolutions USD 679.5M 41.3M 2023-12
Exelixis USD 1.25B 42.18M 2026-06
Glaxosmithkline GBP 17.76B 5.83B 2026-03
Heron Therapeutics USD 229.84M 861K 2026-06
Ionis Pharmaceuticals USD 2.49B 446.73M 2026-06
Ironwood Pharmaceuticals USD 332.29M 58.11M 2026-03
Lexicon Pharmaceuticals USD 186.03M 84.14M 2026-03
Lonza CHF 8B 3.41B 2025-12
Merck USD 36.68B 1.66B 2026-06
Moderna USD 5.82B 45M 2026-06
Myriad Genetics USD 289M 23.8M 2026-06
Nektar Therapeutics USD 589.04M 322.77M 2026-03
Neurocrine Biosciences USD 1.64B 798.6M 2026-06
Pacira USD 615.21M 100.25M 2026-06
Pfizer USD 41.36B 1.46B 2026-06
PTC Therapeutics USD 2.62B 363.36M 2026-06
Sanofi EUR 31.52B 1.36B 2026-06
Sarepta Therapeutics USD 2.22B 86.05M 2026-06
United Therapeutics USD 3.48B 611.7M 2026-06
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12